Patents Assigned to ARIXA PHARMACEUTICALS, INC.
-
Publication number: 20240415847Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: ApplicationFiled: August 14, 2024Publication date: December 19, 2024Applicant: Arixa Pharmaceuticals, Inc.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
-
Publication number: 20240245705Abstract: Pharmaceutical compositions comprise amoxicillin and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of amoxicillin and avibactam in the plasma of a patient. The oral pharmaceutical compositions and methods can be used to treat mycobacterial infections.Type: ApplicationFiled: March 27, 2024Publication date: July 25, 2024Applicant: Arixa Pharmaceuticals, Inc.Inventor: JOAQUIM TRIAS
-
Publication number: 20230210863Abstract: Pharmaceutical compositions comprising a ?-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of ?-lactam antibiotic and avibactam in the system circulation of a patient. The oral pharmaceutical compositions can methods can be used to treat infections caused by bacteria that produce ?-lactamase enzymes.Type: ApplicationFiled: March 13, 2023Publication date: July 6, 2023Applicant: Arixa Pharmaceuticals, Inc.Inventors: Joaquim Trias, Carole Sable, Andrew Nicholls
-
Publication number: 20230201218Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: ApplicationFiled: February 28, 2023Publication date: June 29, 2023Applicant: Arixa Pharmaceuticals, Inc.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
-
Patent number: 11565999Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.Type: GrantFiled: April 6, 2020Date of Patent: January 31, 2023Assignee: Arixa Pharmaceuticals, Inc.Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
-
Patent number: 11180500Abstract: Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.Type: GrantFiled: October 1, 2019Date of Patent: November 23, 2021Assignee: Arixa Pharmaceuticals, Inc.Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
-
Publication number: 20210186983Abstract: Pharmaceutical compositions comprise amoxicillin and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of amoxicillin and avibactam in the plasma of a patient. The oral pharmaceutical compositions and methods can be used to treat mycobacterial infections.Type: ApplicationFiled: December 16, 2020Publication date: June 24, 2021Applicant: Arixa Pharmaceuticals, Inc.Inventor: JOAQUIM TRIAS
-
Patent number: 11008321Abstract: A crystalline form of an avibactam derivative, pharmaceutical compositions thereof, and the use of the crystalline avibactam derivative for treating bacterial infections are provided.Type: GrantFiled: March 10, 2020Date of Patent: May 18, 2021Assignee: Arixa Pharmaceuticals, Inc.Inventor: Sami Karaborni
-
Publication number: 20210060033Abstract: Pharmaceutical compositions comprising a ?-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of ?-lactam antibiotic and avibactam in the system circulation of a patient. The oral pharmaceutical compositions can methods can be used to treat infections caused by bacteria that produce ?-lactamase enzymes.Type: ApplicationFiled: August 27, 2020Publication date: March 4, 2021Applicant: ARIXA PHARMACEUTICALS, INC.Inventors: JOAQUIM TRIAS, CAROLE SABLE, ANDREW NICHOLLS
-
Publication number: 20200339507Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.Type: ApplicationFiled: April 6, 2020Publication date: October 29, 2020Applicant: ARIXA PHARMACEUTICALS, INC.Inventors: ERIC M. GORDON, MATTHEW A.J. DUNCTON, JOHN FREUND
-
Patent number: 10815228Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.Type: GrantFiled: March 12, 2019Date of Patent: October 27, 2020Assignee: ARIXA PHARMACEUTICALS, INC.Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
-
Publication number: 20200291022Abstract: A crystalline form of an avibactam derivative, pharmaceutical compositions thereof, and the use of the crystalline avibactam derivative for treating bacterial infections are provided.Type: ApplicationFiled: March 10, 2020Publication date: September 17, 2020Applicant: ARIXA PHARMACEUTICALS, INC.Inventor: Sami Karaborni
-
Patent number: 10722521Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: GrantFiled: October 16, 2019Date of Patent: July 28, 2020Assignee: ARIXA PHARMACEUTICALS, INC.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
-
Publication number: 20200102307Abstract: Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.Type: ApplicationFiled: October 1, 2019Publication date: April 2, 2020Applicant: ARIXA PHARMACEUTICALS, INC.Inventors: ERIC M. GORDON, MATTHEW A.J. DUNCTON, JOHN FREUND
-
Publication number: 20200046724Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the f-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: ApplicationFiled: October 16, 2019Publication date: February 13, 2020Applicant: ARIXA PHARMACEUTICALS, INC.Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
-
Patent number: 10500211Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: GrantFiled: August 29, 2018Date of Patent: December 10, 2019Assignee: ARIXA PHARMACEUTICALS, INC.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
-
Patent number: 10280161Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.Type: GrantFiled: October 1, 2018Date of Patent: May 7, 2019Assignee: ARIXA PHARMACEUTICALS, INC.Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
-
Patent number: 10093666Abstract: Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.Type: GrantFiled: January 24, 2018Date of Patent: October 9, 2018Assignee: ARIXA PHARMACEUTICALS, INC.Inventor: Eric M. Gordon
-
Patent number: 10085999Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: GrantFiled: March 23, 2018Date of Patent: October 2, 2018Assignee: ARIXA PHARMACEUTICALS, INC.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton